新西兰将资助DADHD药物Vyvanse,在最初6 000多人中简化获得治疗的途径。 New Zealand to fund ADHD drug Vyvanse, simplifying access to treatments for over 6,000 initially.

新西兰的药物购买机构药房将从12月开始资助一种新的ADDHD药物Lisdexamfetamine(Vyvanse),最初使6 000多人受益,五年内增至13 000人。 New Zealand's drug-buying agency, Pharmac, will fund a new ADHD medication, lisdexamfetamine (Vyvanse), starting December, benefiting over 6,000 people initially, rising to 13,000 in five years. 药房还取消了ADDHD和精神病药物的更新标准,简化了获得甲基苯甲酯、毒杀芬胺和modafinil等治疗的机会。 Pharmac also removes renewal criteria for ADHD and narcolepsy medicines, simplifying access to treatments like methylphenidate, dexamfetamine, and modafinil. 这一变化旨在方便获得药品和改善病人的护理。 This change aims to ease medication access and improve patient care.